Literature DB >> 10903235

Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications.

F Arancibia1, S Ewig, J A Martinez, M Ruiz, T Bauer, M A Marcos, J Mensa, A Torres.   

Abstract

The aim of the study was to determine the causes and prognostic implications of antimicrobial treatment failures in patients with nonresponding and progressive life-threatening, community-acquired pneumonia. Forty-nine patients hospitalized with a presumptive diagnosis of community-acquired pneumonia during a 16-mo period, failure to respond to antimicrobial treatment, and documented repeated microbial investigation >/= 72 h after initiation of in-hospital antimicrobial treatment were recorded. A definite etiology of treatment failure could be established in 32 of 49 (65%) patients, and nine additional patients (18%) had a probable etiology. Treatment failures were mainly infectious in origin and included primary, persistent, and nosocomial infections (n = 10 [19%], 13 [24%], and 11 [20%] of causes, respectively). Definite but not probable persistent infections were mostly due to microbial resistance to the administered initial empiric antimicrobial treatment. Nosocomial infections were particularly frequent in patients with progressive pneumonia. Definite persistent infections and nosocomial infections had the highest associated mortality rates (75 and 88%, respectively). Nosocomial pneumonia was the only cause of treatment failure independently associated with death in multivariate analysis (RR, 16.7; 95% CI, 1.4 to 194.9; p = 0.03). We conclude that the detection of microbial resistance and the diagnosis of nosocomial pneumonia are the two major challenges in hospitalized patients with community-acquired pneumonia who do not respond to initial antimicrobial treatment. In order to establish these potentially life-threatening etiologies, a regular microbial reinvestigation seems mandatory for all patients presenting with antimicrobial treatment failures.

Entities:  

Mesh:

Year:  2000        PMID: 10903235     DOI: 10.1164/ajrccm.162.1.9907023

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

Review 1.  [Severe community-acquired and hospital-acquired pneumonia].

Authors:  L Witte; D Drömann
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-03-11       Impact factor: 0.840

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

3.  Bacterial community-acquired pneumonia: risk factors for mortality and supportive therapies.

Authors:  H Lode
Journal:  Intensive Care Med       Date:  2008-12-10       Impact factor: 17.440

Review 4.  Community-acquired pneumonia: identification and evaluation of nonresponders.

Authors:  João Gonçalves-Pereira; Catarina Conceição; Pedro Póvoa
Journal:  Ther Adv Infect Dis       Date:  2013-02

5.  Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia.

Authors:  M M van der Eerden; F Vlaspolder; C S de Graaff; T Groot; H M Jansen; W G Boersma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-04       Impact factor: 3.267

Review 6.  Management of necrotizing pneumonia and pulmonary gangrene: a case series and review of the literature.

Authors:  Neela Chatha; Dalilah Fortin; Karen J Bosma
Journal:  Can Respir J       Date:  2014-05-02       Impact factor: 2.409

Review 7.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Improving outcomes of elderly patients with community-acquired pneumonia.

Authors:  Félix Gutiérrez; Mar Masiá
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  'Non-resolving' pneumonia.

Authors:  Atul Vijay Palkar; Alwyn Rapose
Journal:  BMJ Case Rep       Date:  2012-09-07

10.  The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia.

Authors:  Alexandra McFarlane; Wendy Sligl
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.